Fortress Biotech, Inc. Business Combination, Contingent Consideration, Liability, Current
Fortress Biotech, Inc. (FBIO) had Business Combination, Contingent Consideration, Liability, Current of $637.00 thousand as of 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2017-11-09
- 2017-09-30: Business Combination, Contingent Consideration, Liability, Current $637.00K.
- 2017-06-30: Business Combination, Contingent Consideration, Liability, Current $630.00K.
- 2017-03-31: Business Combination, Contingent Consideration, Liability, Current $623.00K.
- 2016-12-31: Business Combination, Contingent Consideration, Liability, Current $424.00K.
| Period end | Business Combination, Contingent Consideration, Liability, Current |
|---|---|
| 2017-09-30 | $637.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $630.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $623.00K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $424.00K 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |